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PredictionMolecular signatures causing hepatocellular carcinoma (HCC) from chronic infection of hepatitis B virus
(HBV) or hepatitis C virus (HCV) are not clearly known. Using microarray datasets composed of HCV-
positive HCC or HBV-positive HCC, pathways that could discriminate tumor tissue from adjacent non-
tumor liver tissue were selected by implementing nearest shrunken centroid algorithm. Cancer-related sig-
naling pathways and lipid metabolism-related pathways were predominantly enriched in HCV-positive
HCC, whereas functionally diverse pathways including immune-related pathways, cell cycle pathways, and
RNA metabolism pathways were mainly enriched in HBV-positive HCC. In addition to differentially involved
pathways, signaling pathways such as TGF-β, MAPK, and p53 pathways were commonly signiﬁcant in both
HCCs, suggesting the presence of common hepatocarcinogenesis process. The pathway clustering also veri-
ﬁed segregation of pathways into the functional subgroups in both HCCs. This study indicates the functional
distinction and similarity on the pathways implicated in the development of HCV- and/or HBV-positive HCC.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is one of the most fatal cancers
worldwide, and about half million patients die from this disease
each year [1]. Chronic infection of hepatitis B virus (HBV) or hepatitis
C virus (HCV) is the major risk factors for HCC. Although histological
evaluation and clinical manifestation are indistinguishable between
chronic hepatitis patients with HBV or HCV infection [2], gene expres-
sion pattern in HBV- or HCV-infected livers has been reported to be
different [3,4]. Moreover, microarray studies have demonstrated
that HBV and HCV cause hepatocarcinogenesis by different molecular
mechanisms [5–8]. For example, based on the differentially expressed
genes between HBV- and HCV-positive HCC, biological functions suchHepatitis B virus; HCV, Hepati-
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rights reserved.as apoptosis, DNA repair responses, and inﬂammatory pathways have
been differently implicated in two types of HCC [4,5]. Although themi-
croarray revealed the different molecular signatures responsible for
development of HBV-positive HCC or HCV-positive HCC, the different
microarray platforms and heterogeneous clinicopathological nature
of samples used in the experiments makes it hard to obtain common
genes or common signaling pathways that can be applied to all data-
sets. For example, we previously reported that only a small part of
the principle genes in HBV-positive HCC were in common with those
selected from other microarray datasets [9,10]. Moreover, since most
research involving high-throughput data have eventually focused on
only a handful of signiﬁcant genes, it is difﬁcult to obtain biological in-
formation that can be extracted from a network relationship of whole
genes. In addition, individual genes are more susceptible to noise in-
herent to the microarray technology. One of the approaches to over-
come these limitations is using functionally- or structurally-related
pre-deﬁned gene sets, such as pathway, rather than using individual
genes [11,12]. Recent reports also demonstrated that the pathway-
based approach yieldsmore interpretable results on particular cellular
or physiological functions by simplifying the complex structure of a
genetic network [13–15]. A variety of methods have been proposed
to identify pathways associated with the phenotype of subjects, in-
cluding discriminant analysis [16,17] and enrichment methods
[11,18]. Recently, Pang et al. used random forest algorithm to identify
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clusters to understand possible crosstalk between pathways [19,20].
Because biological processes associated with development of HCC
have not been clearly elucidated in pathway level, it is important to
identify the functional changes involved in the development of
HBV-positive HCC or HCV-positive HCC. In this study, we identiﬁed
that cancer-related signaling pathways and lipid metabolism-related
pathways were predominantly enriched in HCV-positive HCC, where-
as diverse functions including immune-related pathways, cell cycle
pathways, and RNA metabolism pathways were mainly enriched in
HBV-positive HCC. In addition, many cancer-related signaling path-
ways were also commonly signiﬁcant in both HBV-positive HCC and
HCV-positive HCC indicating the presence of common hepatocarcino-
genesis mechanism.2. Results
2.1. Assessment of the discrimination methods
The overall analysis procedure is depicted in Fig. 1, in which
diverse classiﬁcation algorithms were implemented to identifyGene expression data
(Tumor/Non-tumor)
Training Test
Random iteration 
(n=1,000)
(Tumor/Non-Tumor) (Tumor/Non-Tumor)
Prediction error rate
Model Predict
Important pathways
Pathway information
Classification methods
Fig. 1. A schematic illustration of the analysis strategy. Initial dataset consisting of HCC
and adjacent non-tumor liver tissue was randomly divided into training and test sets.
Using genes included in each pathway, a training model discriminating tumor tissue
from adjacent non-tumor liver tissue was built by implementing various classiﬁcation
algorithms: nearest shrunken centroid (or prediction analysis of microarrays; PAM),
random forest (RF), support vector machine (SVM), linear discriminant analysis
(LDA) and k-nearest neighbor (KNN) classiﬁer. Then, the model of each pathway
was evaluated in the test set. This procedure was repeated 1000 times with random
training and test sets. Finally, the averaged test error rate was measured to select sig-
niﬁcant pathways.pathways using the random training/test method. We measured
the efﬁciency of ﬁve different models (PAM, RF, SVM, KNN and
LDA) on class discrimination, namely, tumor versus adjacent non-
tumor liver tissue, using three different HCC microarray datasets:
HCV-positive dataset, HBV-positive dataset and HBV- or HCV-
positive dataset. Clinicopathological information about the three
datasets is shown in Supplementary Table 1. Fig. 2 shows the corre-
lation plot of averaged test error rate for each pathway according to
classiﬁcation methods on the HCV-positive HCC dataset. PAM, RF,
and SVM displayed similar distribution of averaged test error rate
with correlation coefﬁcient exceeding 0.6. The scatter plot matrixes
for the HBV-positive HCC dataset and HBV- or HCV-positive HCC
dataset also showed similar results (Supplementary Figs. 1 and 2).
We selected PAM as the main discrimination method for the follow-
ing analysis since this algorithm was reported to be excellent in
microarray analysis [9,21].
2.2. Identiﬁcation of pathways
By implementing PAM, we identiﬁed pathways implicated in
liver tumorigenesis and compared these pathways with those
from the GSA algorithm, a recently-reported pathway-based method
[18]. Table 1 shows the ﬁve top-ranked pathways having minimum
averaged test error rate in each dataset. The full list of pathway is
shown in Supplementary Table 2. Pathways with minimum aver-
aged test error rate of 0.05 and 0.1 were selected to be signiﬁcant
in HCV-positive HCC dataset and HBV-positive HCC dataset, re-
spectively. PAM and GSA algorithms displayed a more similar re-
sult in the HBV-positive HCC dataset than in the HCV-positive
HCC dataset. For example, in the HBV-positive HCC dataset, many
pathways with a false discovery rate (FDR) of 0 by GSA were
also selected as signiﬁcant pathways with the minimum averaged
test error rate by PAM. In the HCV-positive HCC dataset, pathways
with low averaged error rate in PAM displayed high FDR in GSA.
Actually, a large number of pathways selected by GSA displayed
poor averaged test error rates, suggesting that PAM is the more
suitable method to identify signiﬁcant pathways. To investigate
the distribution of pathways among datasets, we selected the
100 top-ranked pathways having low averaged test error rates
by PAM or low FDR by GSA from each dataset. Figs. 3A and B
show the Venn diagram for the distribution of these pathways
among three datasets. For the PAM algorithm, 11 pathways were
commonly selected in all datasets (Fig. 3A), while 10 pathways
were common using GSA (Fig. 3B). When we focused on only
the HCV-positive dataset and HBV-positive dataset, 23 pathways
were common in both types of HCC datasets by the PAM and
GSA algorithms. In the HBV- or HCV-positive HCC dataset, which
contained HCV-positive samples and HBV-positive samples, more
pathways were in common with the HBV-positive HCC dataset
(52 pathways by PAM) than the HCV-positive HCC dataset (23
pathways by PAM). This pattern of pathway distribution was also
conﬁrmed by GSA. The biological functions of commonly or differ-
ently distributed pathways among datasets are shown in Fig. 3C.
Intriguingly, cancer-related signaling pathways and lipid metabolism
pathways were predominantly enriched in the HCV-positive HCC
dataset, whereas diverse pathways including immune-related path-
ways, cell cycle pathways and RNA metabolism pathways were
enriched in the HBV-positive HCC dataset. Some cancer-related sig-
naling pathways and membrane-related maintenance functions
were commonly signiﬁcant in both datasets.
2.3. Genes implicated in pathways
Although we identiﬁed commonly selected pathways in the HCV-
positive HCC dataset and HBV-positive HCC dataset, this did not in-
dicate the presence of common genes implicated in those pathways.
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Fig. 2. Scatter plot matrix with histogram of averaged test error on the diagonal and pairwise comparisons of the averaged test error among the ﬁve different prediction methods
(PAM, RF, SVM, KNN and LDA) on the off-diagonal for the HCV-positive HCC dataset with correlation coefﬁcient.
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pathway, axon guidance pathway and transforming growth factor-
beta (TGF-β) signaling pathway, which were all enriched in both
the HCV-positive HCC dataset and HBV-positive HCC dataset, the ex-
pression pattern of genes was different depending on the dataset
(Supplementary Fig. 3). Therefore, the activities of these pathways
might be different in each dataset.2.4. Pathway clusters
We classiﬁed pathways into subgroups based on the functional
categories in Fig. 3C. Next, pathway clusters were measured based
on similarity of class discrimination ability of pathways. Although
the overall cluster structure was different between the HCV-
positive HCC dataset and HBV-positive HCC dataset, cancer-related
signaling pathways and metabolism-related pathways were clus-
tered into separate subgroups as Class 1 and Class 2, respectively,
in both datasets (pb0.01) (Fig. 4). This result suggests the presence
of network of pathways commonly acting on the development of
both types of HCC.3. Discussion
HBV and HCV are completely different viruses. HBV contains a
double-stranded DNA genome that integrates into the host genome,
while HCV is a RNA virus that replicates in the cytoplasm of the cell
[2]. Despite their different life cycles and genomes, they share com-
mon characteristics in chronic liver diseases such as hepatitis, which
can progress to cirrhosis and HCC. Although this process is not distin-
guishable by histological examination or clinical manifestations,
molecular investigations have identiﬁed the differentially expressed
genes between HBV- and HCV-positive HCC [5–8]. This result strongly
suggests that diagnostic and therapeutic targets for HCC should be
considered differently between HBV- and HCV-positive HCC.
In the present study, we measured a pathway's ability to discrim-
inate tumor tissues from adjacent non-tumor liver tissues from the
HCV-positive HCC dataset or HBV-positive HCC dataset. When this
approach was compared with conventional gene-based approach, it
was evident that pathway-based method was less affected by exper-
imental variations from multiple microarray platforms. For example,
23% of pathways were commonly selected between HCV-positive
HCC dataset and HBV-positive HCC dataset in our approach, whereas
Table 1
Signiﬁcant pathways associated with each HCC dataset.
Pathway PAM GSA⁎
Error rate⁎⁎ P⁎⁎ CV Error⁎⁎⁎ P⁎⁎⁎ Score P FDR
HCV-positive Sphingolipid metabolism 0.050 0.054 0.057 0.006 0.253 0.15 0.642
PDGF pathway 0.057 0.163 0.057 0.028 −0.064 0.33 0.768
Downstream signal transduction 0.059 0.199 0.046 0.032 0.323 0.08 0.555
Small cell lung cancer 0.060 0.271 0.057 0.057 0.278 0.05 0.555
Hedgehog signaling pathway 0.061 0.213 0.057 0.038 −0.367 0.04 0.523
HBV-positive TGF beta signaling pathway 0.102 0.010 0.094 0.002 −0.667 0.00 0.000
Mitotic M-M/G1 phases 0.106 0.159 0.099 0.107 0.398 0.00 0.000
Antigen processing and presentation 0.116 0.020 0.109 0.019 0.804 0.02 0.331
mRNA splicing 0.119 0.173 0.109 0.125 0.414 0.00 0.000
Apoptosis 0.121 0.169 0.115 0.133 0.510 0.00 0.000
HBV- or HCV-positive Metabolism of proteins 0.052 0.139 0.049 0.077 0.472 0.00 0.000
Inﬂuenza life cycle 0.055 0.100 0.043 0.038 0.507 0.00 0.000
Lysosome 0.056 0.175 0.049 0.123 0.333 0.04 0.276
Platelet activation 0.058 0.260 0.056 0.266 −0.090 0.17 0.765
Translation 0.058 0.040 0.056 0.014 0.473 0.01 0.112
⁎ For GSA, score represents gene set score measured by maxmean statistic. P-value and FDR were obtained using restandardization method implemented in GSA R package.
⁎⁎ Error rate was computed by averaging over-all the prediction error rates. P-value was measured by random permutation.
⁎⁎⁎ CV Error represents 10-fold cross-validated error rate. P-value was measured by random permutation.
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and Supplementary Fig. 4). The clinicopathological characteristics
also support the similar pathophysiology of three HCC datasets;
HCV-positive dataset, HBV-positive dataset and HBV- or HCV-
positive dataset (Supplementary Table 1). Variables related with
liver pathology; ﬁbrosis stage distribution, total bilirubin, alanine
aminotransferase and alpha-fetoprotein level were similar among
datasets. Tumor characteristics such as tumor number, size and stage
also did not signiﬁcantly differ among datasets, although the HBV-
positive HCC dataset was composed of more poorly differentiatedSignaling pathways (79)
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351S.Y. Lee et al. / Genomics 99 (2012) 347–354depending on the status of viral infection. Involvement of signaling
pathways such as diverse cancer-related, apoptosis, Wnt and janus ki-
nase/signal transducer and activator of transcription (JAK/STAT) path-
ways indicates de-regulation of signal pathways in HCV-positive HCC
(Table 1 and Supplementary Table 2). It has been reported that HCV
infection de-regulates many signal pathways and causes tumor devel-
opment, although which viral protein plays a key role has not been
fully elucidated [22,23]. In addition to cancer- and signal pathways,
we identiﬁed other functional changes in lipid metabolism in
HCV-positive HCC. The glycero-phopholipid metabolism pathway,
inositol-phosphate metabolism pathway and sphingolipid metabo-
lism pathway were enriched in HCV-positive HCC. These ﬁndings are
consistent with the recent report that HCV infection induces abnor-
mality of lipid metabolism and contributes to hepatic steatosis and
the development of cancer [24,25]. In addition, the presently-
identiﬁed autophagy pathway was reported to be critical in suppress-
ing innate antiviral immunity in HCV infection [26].
While signaling pathways were mainly enriched in HCV-positive
HCC, relatively diverse biological functions were implicated in HBV-
positive HCC suggesting that hepatocarcinogenesis from chronic
HBV infection causes more various changes in cellular function than
in HCV infection. Although partly involved also in HCV-positive HCC,
diverse functional pathways including immune pathways, cell cycle
pathways and RNA metabolism pathway were selected as signiﬁcant
pathways in HBV-positive HCC. Previous studies have indicated that
dynamic interactions among HBV, hepatocytes and the host immune
system may determine viral persistence and disease progression
[5,6,27]. Recently, genetic variations at the locus involved in immune
response were also reported to be risk factors for HCC [28]. More-
over, involvement of S-phase kinase-associated protein 2 (SKP2)-
mediated p21 degradation pathway in HBV-positive HCC, a cell
cycle pathway, is consistent with the recent report that mutation inHBV core promoter increases the risk for HCC development by up-
regulating SKP2 and then down-regulating p21 via ubiquitin-
mediated proteasomal degradation [29]. In addition, enrichment of
a group of RNA processing pathways in HBV-positive HCC may also
be critical in HBV-positive HCC, as evidenced by the ﬁnding that
aberrant splicing of mRNA is associated with HCC development and
progression [30,31].
These differences between HBV- and HCV-positive HCCs indicate
the different molecular mechanism of hepatocarcinogenesis caused
by two types of viruses. Although cirrhosis induced by HBV or HCV
is a commonmajor risk factor for HCC development, it has been dem-
onstrated that several viral factors including the HBx, pre-S2/S and
spliced protein in HBV, and Core, E2 and NS5A in HCV have oncogenic
properties acting on different targets in the host [32]. Furthermore,
HBV integrated into host genome leads to global changes in genomic
function and chromosomal instability.
Previous reports were mainly focused on the identiﬁcation of
difference between HBV- and HCV-positive HCC. However, the pre-
sent study identiﬁed that many cancer-related signaling pathways
are commonly signiﬁcant in both types of HCC, which implies
the presence of a common hepatocarcinogenesis process. For ex-
ample, the TGF-β pathway, MAPK pathway and p53 pathway
were included in this category, all of which were already reported
to be involved in HCC development and progression [33–35]. An-
other notable common feature in both HBV-positive HCC and
HCV-positive HCC was membrane-related maintenance function in-
cluding actin cytoskeleton, focal adhesion and axon guidance path-
ways (Supplementary Table 2). Because maintenance of tissue
homeostasis is important in the control of cell growth and differ-
entiation, de-regulated tissue maintenance is critically implicated
in tumor progression and metastasis in HCC [36,37]. For example,
tight junctions play a key role in HCV entry into host cells [38].
352 S.Y. Lee et al. / Genomics 99 (2012) 347–354In addition to signaling pathways, energy metabolism pathways
including glycolysis have emerged as a potent driving force of
liver tumorigenesis [39,40]. We also identiﬁed that general meta-
bolic pathways such as glycolysis, oxidative phosphorylation,
amino-acid metabolism and nucleotide metabolism were also
highly signiﬁcant in both types of HCC. Considering that Wnt sig-
naling induces a shift in the glucose metabolism from oxidative
phosphorylation to glycolysis in the liver [41], the signaling path-
ways regulating general metabolism may be a key target to control
the HCC development.
Although we applied pathway-based class discrimination method
to overcome the limitation associated with single gene-based ap-
proach, problems involving small size of samples and different
types of microarray platforms can still inﬂuence on process of the
pathway identiﬁcation. Therefore, it would be important to increase
sample numbers with diverse types of microarrays to demonstrate
the efﬁcacy of our pathway-based approach in extracting signiﬁcant
biological information.
4. Conclusions
In conclusion, we identiﬁed diverse pathways implicated in HCC
development according to the status of viral infection. Our ﬁndings
clearly demonstrate the differences and similarities in biological
functions between HBV- and HCV-positive HCC, and the possible
presence of a global network of pathways in the development of
both types of HCC.
5. Materials and methods
5.1. HCC dataset
Three different microarray datasets of HCC were used in our
study. The ﬁrst set (HCV-positive HCC dataset) was composed of
87 only HCV-positive specimen containing 43 HCCs and 44 non-
tumor liver tissues [42] in which, total RNA from frozen samples,
or human reference RNA was labeled with ﬂuorescent dyes (Cy5
and Cy3, respectively), and hybridized on arrays (Agilent Technologies).
Raw microarray data was archived in Gene Expression Omnibus
(GSE17856). For normalization, the log2 values of probe intensity
ratio (Cy5/Cy3) were smoothed by LOWESS method [43]. Multiple
probes per single gene were averaged and 19,371 genes were ﬁnally
included for study.
As the second microarray dataset, we used only HBV-positive
samples (HBV-positive HCC dataset, GSE14811), previously reported
by us [10]. This dataset was composed of 96 HCCs and 96 pair-
matched non-tumor liver tissues. Total RNA from each frozen sample
and placental reference RNA were labeled with ﬂuorescent dyes (Cy5
and Cy3, respectively) and hybridized with approximately 14,000
cDNAs printed onto glass microscope slides. The log2 ratios of probe
intensity (Cy5/Cy3) were normalized using LOWESS method. Espe-
cially, space- and intensity-dependent LOWESS method was applied
to eliminate intensity bias associated with manufacturing process of
spot-type slide microarray in this dataset [44]. After averaging ratios
of multiple probes per single gene, 6122 genes were included in the
present study.
Finally, the third dataset (HBV- or HCV-positive HCC dataset,
GSE10143) included 162 samples (80 HCCs and 82 non-tumor liver
tissues) composed of heterogeneous viral types of specimen from
Hosida et al. [45]. The samples had been kept in formalin-ﬁxed and
parafﬁn-embedded blocks. Total RNA extracted from tissues was con-
verted into cDNA and then was employed to the cDNA-mediated
annealing, selection, extension, and ligation (DASL) assay (Illumina).
The ampliﬁed products were hybridized to a bead microarray. The
one color signal intensities of quality controlled 6100 genes werenormalized using quantile method to make the distribution of
probe intensities of each array the same [43].5.2. Classiﬁcation algorithm
Fig. 1 shows a schematic diagram of overall procedure applied
to identify signiﬁcant pathways. Initially, each microarray dataset
was split into two groups randomly as the training and test set com-
posed of 60% and 40% of the samples, respectively. With pre-deﬁned
genes belonging to each pathway, the prediction model was built by
implementing ﬁve different algorithms in the training set to discrim-
inate tumor samples from adjacent non-tumor samples; nearest
shrunken centroid (or Prediction Analysis of Microarrays; PAM)
[21], random forest (RF) [19], support vector machine (SVM) [46],
linear discriminant analysis (LDA), and k-nearest neighbor classiﬁer
(KNN). Finally, the prediction error rate was evaluated on indepen-
dent test data. This procedure was repeated 1000 times to extract
as much information as possible from all samples. Then, the mean
test error rate was computed by averaging over-all the prediction
error rates for a pathway. Finally, to estimate the statistical signiﬁ-
cance of an averaged test error rate, the permutation-based ap-
proach was used. The gene labels (gene symbol) were randomly
permuted 1000 times. For each permutation, the random test error
rate was measured as the same procedure used in the original data-
set. By comparing the original averaged test error rate with permu-
tated random error rates, the statistical signiﬁcance for a pathway
was estimated. We applied a gene-based permutation rather than a
class (phenotype)-based permutation, reﬂecting the fact that the ex-
pression of many genes are already changed between HCC and adja-
cent non-tumor liver tissues [9,10].
We also measured the pathway prediction efﬁcacy using a cross-
validation (CV) method. In that analysis, the prediction model was
built and evaluated on 10-fold CV for PAM. The statistical signiﬁ-
cance of cross-validated error rate was also measured using gene-
based random permutation method (n=1000). All procedures
were performed using R (v2.12.0; the R source code for our program
is available upon request). On the other hand, t-test was used for se-
lection of genes discriminating between HCC and adjacent non-
tumor liver tissue.5.3. Gene set analysis (GSA)
GSA is an improved version of Gene Set Enrichment Analysis
(GSEA) [11,18]. GSA measures the gene-set score for each gene set
and searches for signiﬁcantly correlated gene sets with the phenotyp-
ic class. For comparison with our method, we performed GSA algo-
rithm using GSA R package (v1.03).5.4. Pathway information
The pathway database was obtained from Molecular Signatures
Database (MSigDB) [11], from which manually curated pathway in-
formation of Kyoto Encyclopedia of Genes and Genomes (KEGG, 186
pathways) [47], BioCarta (217 pathways, http://www.biocarta.com/
genes/allpathways.asp) and Reactome database (430 pathways)
[48] were initially included in this study. From a total of 833 path-
ways, only pathways containing expression values of at least ﬁve
genes were included in this study. Therefore, 818 pathways (185
from KEGG, 214 from BioCarta and 419 from Reactome) for HCV-
positive HCC dataset, 680 pathways (175 from KEGG, 159 from
BioCarta and 346 from Reactome) for HBV-positive HCC dataset and
799 pathways (183 from KEGG, 216 from BioCarta and 400 from
Reactome) for HBV- or HCV-positive HCC dataset were used.
353S.Y. Lee et al. / Genomics 99 (2012) 347–3545.5. Pathway cluster
The similarity of pathways was measured by the consensus clus-
tering method [49], which is a tool for unsupervised class discovery
involving subsampling. The matrix of classiﬁcation error rate mea-
sured on each sample and each pathway using PAM algorithms was
used for clustering (ConsensusClusterPlus R package v1.0.1). We in-
cluded 100 top-ranked pathways from KEGG having low averaged
test error. Cluster count (k) of 5 was applied after graphical deter-
mination of cumulative distribution function. Statistical signiﬁcance
for functional clustering of pathways was measured by Chi-square
test performed in R.
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